Sapient Capital LLC Has $741,000 Stock Holdings in Stryker Corporation $SYK

Sapient Capital LLC decreased its position in shares of Stryker Corporation (NYSE:SYK) by 54.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,250 shares of the medical technology company’s stock after selling 2,647 shares during the quarter. Sapient Capital LLC’s holdings in Stryker were worth $741,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. Sankala Group LLC acquired a new stake in Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker during the fourth quarter worth about $27,000. Finally, DJE Kapital AG acquired a new position in Stryker in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

SYK opened at $340.73 on Tuesday. The company has a market capitalization of $130.62 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 2.08 and a beta of 0.76. The business’s 50-day moving average price is $317.77 and its two-hundred day moving average price is $334.62. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts expect that Stryker Corporation will post 15.01 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio is 36.48%.

Insider Transactions at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SYK shares. Truist Financial increased their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday. BTIG Research decreased their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research report on Friday. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Citizens Jmp dropped their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday. Finally, Piper Sandler cut their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.